The Association of the British Pharmaceutical Industry (ABPI) commented on the European Council’s November endorsement of
the agreement on Brexit and the UK’s Political Declaration setting out the framework for the future relationship between the UK
and the EU. Recognizing the significance of the development, ABPI Chief Executive Mike Thompson said: “The terms of the deal
mean that medicines will continue to reach the patients who need them when the UK leaves the EU in March … It also includes
the ‘possibility of cooperation’ between the regulators, the MHRA and the EMA.”
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
